

HYBRIDOMA DEVELOPMENT AND MONOCLONAL ANTIBODY GENERATION


ChemPartner provides premium monoclonal antibody services. Our advanced hybridoma platform is **validated by more than 60 therapeutic projects and a large number of reagent mAb projects.**

A number of key technologies including biofunctional protein production, over-expressing stable cell line generation, tolerance breaking technologies, success guaranteed hybridoma generation, high throughput cell-based screening and media compatible bioassay development, and protein analytics are integrated into this platform to ensure the success of mAb development for therapeutic candidates and broad range of assay applications.

We deliver antibodies to successfully meet the assay and product development specifications of our global biopharma clients. We are continuously improving our service platforms and expanding our capabilities in areas such as GPCR/ion-channel antibody and ADC antibody discovery.

ANTIGEN AND IMMUNOGEN	WELL-ESTABLISHED SCREENING ASSAYS	
<ul style="list-style-type: none"> Recombinant protein production Stable cell line generation Peptide/compound synthesis and protein conjugation Plasmid DNA construction and bullet preparation 	BINDING ASSAYS	
	Flow cytometry (FACS)	Low-medium throughput
	Accumen microplate cytometry	High throughput
	Immunocytochemistry (ICC/IHC)	Low throughput
ANIMAL IMMUNIZATION	FUNCTIONAL ASSAY	
<ul style="list-style-type: none"> SPF grade and multiple species/strain CPSJ mice with superior immune response Transgenic mice for fully human antibody generation Genetic immunization 	<ul style="list-style-type: none"> Proliferation assay Apoptosis assay Migration assay Soft agar colony formation assay Cell signaling assay Luciferase reporter assay Cytokine releasing assay FLIPR assay Antibody internalization assay ADCC/CDC T cell stimulation assay Mixed lymphocyte reaction Cell adhesion assay Antigen specific T cell assay 	Assays established with recombinant cell lines or endogenous cell lines and successfully used in hybridoma screening and antibody characterization
HYBRIDOMA DEVELOPMENT		
<ul style="list-style-type: none"> PEG or electrofusion as desired Guaranteed success for positive hybridoma High throughput cell based screening assay Functional assay for early stage screening 		
MAB PRODUCTION		
<ul style="list-style-type: none"> Master or working cell banking In vitro production and affinity purification Production scale of mgs – grams Purity >95% and endotoxin at 1EU/mg or lower 		

PROJECT TIMELINE



REAGENT PROJECTS

4-6 MONTHS

- SPF animals and multiple species/strains
- Specialized animal strains with superior immune response to conservative antigens
- Proprietary genetic immunization procedures
- Immune tolerance breaking technology available
- Fully human antibody generation from transgenic mice
- Integrated services for therapeutic antibody discovery

THERAPEUTIC PROJECTS

10-12 MONTHS

- High throughput cell-based screening with Acumen microplate cytometer
- Well-established bioassays for hybridoma screening and mAb characterization
- Affinity assessment and rank
- Biophysical analysis available
- Manufacturability assessment available
- Guaranteed success in reagent antibody generation
 - Anti-idiotypic antibody
 - IHC, FACS, ELISA, WB

DELIVERABLES

- Screening data from all phase
- Selected hybridoma cell line
- Purified antibody with COA
- Antibody characterization data package
- Lead antibody panel

ADDITIONAL SERVICES

- ADC development
- PK/PD assessment
- Large molecule PK expertise
- Toxicokinetic evaluation
- In vivo efficacy study

LEARN MORE AT [CHEMPARTNER.COM/SERVICES/BIOLOGICS-DISCOVERY/ANTIBODY-DISCOVERY/HYBRIDOMA/](https://chempartner.com/services/biologics-discovery/antibody-discovery/hybridoma/)